Quantcast
Last updated on April 18, 2014 at 12:57 EDT

Pfizer/Bristol-Myers Squibb’s Apixaban Will Become Decision Resources’ Proprietary Clinical Gold Standard in 2013 and Through 2018 for the Treatment of Venous Thromboembolism

April 28, 2010

WALTHAM, Mass., April 28 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that for the treatment of venous thromboembolism, Pfizer/Bristol-Myers Squibb’s apixaban will earn Decision Resources’ proprietary clinical gold standard status in 2013 (following its approval for the indication in that year) and through 2018. Apixaban’s main benefits over existing drugs, including the current gold standard regimen GlaxoSmithKline’s Arixtra/Bristol-Myers Squibb’s Coumadin, are that it does not require monitoring, it is dosed orally throughout the entire course of treatment, and it is not likely to require dose-adjustment for reasons such as renal impairment or weight.

The new report entitled Venous Thromboembolism (Treatment and Secondary Prophylaxis): Emerging Oral Anticoagulants Are Set to Challenge the Treatment Paradigm also finds that a drug that does not require monitoring for the treatment and secondary prophylaxis of venous thromboembolism would earn 60 percent patient share in the venous thromboembolism market according to surveyed U.S. hematologists. In contrast, in Europe, such a drug would earn a lower patient share of 43 percent according to surveyed European physicians.

Coumadin is currently the standard of care for the secondary prophylaxis of venous thromboembolism in the majority of patients, for whom injectable therapy with a low-molecular-weight heparin is impractical in the long-term. Even with regular monitoring, the difficulties associated with Coumadin are a leading cause of drug-related adverse events and emergency room visits.

“Because of the burdensome monitoring required to ensure safe venous thromboembolism treatment with Coumadin, interviewed experts are enthusiastic about emerging drugs that have predicable dose-response profiles, a lower rate of drug-drug and drug-food interactions and, therefore, no need for regular monitoring,” stated Decision Resources’ analyst Matthew Killeen Ph.D. ” A number of such drugs are in late-stage development, including Boehringer Ingelheim’s Pradaxa, Bayer/Ortho-McNeil’s Xarelto and apixaban. These novel drugs should have a profound impact on Coumadin usage and greatly increase the value of the venous thromboembolism treatment and secondary prophylaxis market over the next ten years.”

About the Report

Venous Thromboembolism (Treatment and Secondary Prophylaxis): Emerging Oral Anticoagulants Are Set to Challenge the Treatment Paradigm is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    For more information, contact:

    Decision Resources, Inc.
    Christopher Comfort
    781-296-2597
    ccomfort@dresources.com

SOURCE Decision Resources


Source: newswire